Clinical trials: Pharyngeal Cancer
HPV, Oropharynx Cancer
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC.
- Conditions
- HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy
- Trial name
- NCT05307939
- Testing
- HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Nasopharyngeal Carcinoma
Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma
This study is a phase II clinical study of Cadonilimab (AK104) combined with chemotherapy in the treatment of PD-1 inhibitor-resistant nasopharyngeal carcinoma.
- Trial name
- NCT05790200
- Testing
- Cadonilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Oropharyngeal Carcinoma, Immune Checkpoint Inhibitor
Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC
Human papillomavirus (HPV)-related oropharyngeal carcinoma are exquisitely radiosensitive. Several studies attempted to reduce the toxicities of treatments through reduced-dose radiation and showed promising results, but all data…
- Conditions
- Oropharyngeal Carcinoma, Immune Checkpoint Inhibitor, De-escalation
- Trial name
- NCT04867330
- Testing
- Toxicities reduced treatment arm
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC
This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and safety of radical chemoradiotherapy plus oral capecitabine/teggio for 1 year in patients with N3.
- Trial name
- NCT04220528
- Testing
- Capecitabine/Tiggio
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
The purpose of this study is to test the hypothesis that a combined Immuno-Oncology (IO) strategy would see efficacy in a virally driven cancer like Nasopharyngeal Carcinoma (NPC).
- Trial name
- NCT03097939
- Testing
- Ipilimumab, Nivolumab
- Where
- Singapore
- Volunteers
- 113 people
- Sponsor
- National Cancer Centre, Singapore
Nasopharyngeal Carcinoma
Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
This is a phase 2, single-arm, multicenter clinical trial, with the purpose to evaluate the therapeutic efficacy, safety, and tolerability of PD-1 Blockade nivolumab combined with a deintensified chemoradiotherapy by sparing…
- Trial name
- PLATINUM (NCT03984357)
- Testing
- PD-1 blocking antibody, Gemcitabine, Cisplatin
- Where
- 6 sites in China
- Volunteers
- 152 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
The aim of this study is to evaluate the efficacy, adverse reactions, nutritional status analysis, and quality of life analysis of Toripalimab Plus Induction Chemotherapy Followed by Radiation Therapy Combined with Omega-3 in the…
- Trial name
- NCT07136519
- Testing
- Toripalimab, Omega-3, radiotherapy
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Guangdong Medical University
Nasopharyngeal Carcinoma (NPC)
Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma
Immunotherapy combined with chemoradiotherapy has become standard care for locally advanced nasopharyngeal carcinoma, yet radiotherapy-induced lymphopenia may impair the efficacy of concurrent PD-1 blockade.
- Trial name
- NCT07706985
- Testing
- Toripalimab combined with Nimotuzumab, Nimotuzumab
- Where
- China
- Volunteers
- 566 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma
The purpose of this trial is to examine the role of camrezlizumab in addition to carbon-ion radiotherapy (CIRT) for patients with locally recurrent nasopharyngeal carcinoma.
- Trial name
- NCT04143984
- Testing
- Induction chemotherapy, Carbon-ion radiotherapy, Camrelizumab
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare the survival and toxicity of GP (gemcitabine and cisplatin) vs. PF (cisplatin and fluorouracil) as induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) for…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
- Trial name
- NCT03840421
- Testing
- gemcitabine and cisplatin, cisplatin and fluorouracil, IMRT
- Where
- China
- Volunteers
- 468 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
VK-2019-001 is a 1/2a trial of the oral EBNA-1 targeting agent VK-2019 in patients with EBV-positive recurrent or metastatic NPC to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D), as well as to…
- Trial name
- NCT03682055
- Testing
- VK-2019
- Where
- 6 sites in United States, China and 3 more
- Volunteers
- 14 people
- Sponsor
- Cullinan Therapeutics Inc.
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Radiation Toxicity
- Trial name
- NCT00003251
- Testing
- amifostine trihydrate, cisplatin, paclitaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Illinois Chicago
Head and Neck Cancer, Dysphagia
Training Swallowing Initiation During Expiration
Head and neck cancers have escalated to epidemic levels in the United States, and survivors are suffering from life-long, devastating swallowing disorders with limited therapeutic options.
- Conditions
- Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia, Oropharynx Squamous Cell Carcinoma
- Trial name
- NCT05278039
- Testing
- Respiratory-Swallow Phase Training, Swallow Practice
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Northwestern University
Head and Neck Cancer, Head and Neck Neoplasms
Arabic PRO Measures for Head and Neck Cancer Radiotherapy.
The goal of Arabic patient-reported outcome measures during radiotherapy for head and neck cancer is to test the patient-reported outcome measure (PROM) tools.
- Conditions
- Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer
- Trial name
- PROMs (NCT06662929)
- Testing
- Radiation
- Where
- Saudi Arabia
- Volunteers
- 125 people
- Sponsor
- King Saud University
Oral Cavity Neoplasm, Oropharyngeal Neoplasm
ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
This randomized phase IIb trial studies how well ACTOplus met extended release (XR) works in treating in patients with stage I-IV oral cavity or oropharynx cancer that are undergoing definitive treatment.
- Conditions
- Oral Cavity Neoplasm, Oropharyngeal Neoplasm, Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7, Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7
- Trial name
- NCT02917629
- Testing
- Laboratory Biomarker Analysis, Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet, Pharmacological Study
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors
Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Cadonilimab in combination with gemcitabine/cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05898256
- Testing
- Cadonilimab, Gemcitabine, Cisplatin
- Volunteers
- 20 people
- Sponsor
- Guangxi Medical University
Nasopharyngeal Cancer
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
Nasopharyngeal carcinoma is biologically different from traditional head and neck squamous cell carcinoma. The mainstay treatment for locally advanced nasopharyngeal carcinoma is cisplatin-based concurrent chemoradiation.
- Trial name
- NCT05628922
- Testing
- Toripalimab, Induction chemotherapy and concurrent chemoradiation
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Fudan University
Laryngeal Disease, Laryngeal Lesions
Benefit of Enhanced Contact Endoscopy in Pre-histological Diagnosis of Laryngeal and Hypopharyngeal Mucosal Lesions
The focus of the study is to verify the role of enhanced contact endoscopy in early identification of high-risk vascular patterns of precancerous and malignant mucosal changes in ear-nose-throat (ENT) patients, in comparison with…
- Conditions
- Laryngeal Disease, Laryngeal Lesions, Hypopharyngeal Lesions, Suspected Laryngeal Cancer
- Trial name
- NCT04777474
- Testing
- Enhanced contact endoscopy, Narrow band imaging, IMAGE1S imaging
- Where
- 2 sites in Czechia
- Volunteers
- 150 people
- Sponsor
- University Hospital Ostrava
Nasopharyngeal Carcinoma
Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma
A total of 120 patients with pathologically confirmed locally advanced low-risk nasopharyngeal carcinoma were enrolled. They were randomly divided into two groups, with 60 patients in each group.
- Trial name
- NCT02237924
- Testing
- endostar, DDP, IMRT
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Precancerous Conditions, Leukoplakia
Natural History of Oro-pharyngeal Cancer Precursors
Oro-pharyngeal cancers can develop from squamous dysplastic precursor lesions, which occur in a subset of common white (leukoplakia), red (erythroplasia), or mixed oro-pharyngeal plaques.
- Conditions
- Precancerous Conditions, Leukoplakia, Erythroplasia, Oral Papillomas
- Trial name
- NCT00179361
- Where
- United States
- Volunteers
- 374 people
- Sponsor
- Albert Einstein College of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.